Japan designates N-desethyl protonitazene, 5-MeO-MET and 2-F-tropacaine as temporary prefectural bans precede national control

Japan designated three compounds on October 27, 2026: N-desethyl protonitazene, 5-MeO-MET and 2-F-tropacaine. National control under the Pharmaceuticals and Medical Devices Act takes effect November 6, while Tokyo, Osaka, Chiba, Aichi and Gunma imposed local restrictions effective October 28. The article describes prefectural bans as a temporary bridge that closes the nine-day gap before national listing. Historical records from Aichi, Gunma and Tokyo show that hundreds of prior local designations later lapsed when compounds entered the national list or were classified as narcotics. The evidence behind the three compounds differs: 2-F-tropacaine has confirmed domestic circulation in Chiba, 5-MeO-MET has international regulatory and pharmacological records, and N-desethyl protonitazene has been linked to seizures and toxicology findings in the United States. Japan’s notices provide no compound-specific trigger or reported harm, applying a prospective legal standard based on likely central nervous system effects and health risk.